Abstract:Autophagy fundamentally refers to a process where cells enclose their own cell organelles with isolated membrane and deliver them to lysosomes for degradation, servicing as a nonspecific degradation mechanism of autologous proteins. Autophagy is induced above basal levels in response to nutrient deprivation or trophic factor withdrawal to sustain metabolism by producing catabolites. In this context, autophagy acts as a cytoprotective mechanism for cells to protect themselves from extracellular stresses. However, in a culture using cells in which autophagy-related genes were suppressed by siRNA and to which an autophagy inhibitor, 3- methyladenine (3-MA), was added, cytotoxic effects of some anticancer agents on cancer cells were diminished. Based on these results, the concept of caspase-independent cell death via autophagy, which is designated as type II programmed cell death (PCD) in contrast to apoptosis as type I PCD, has been receiving increased attention. We here report that treatment of AML cells with low does-Ara-C induces autophagy and enhances its cytocidal effect on AML cells by combined treatment with G-CSF. Treatment of AML cell line U937 cells with 1 to 50 ng/ml of Ara-C induced cell growth inhibition in a dose-dependent manner. Exposure to the higher concentrations of Ara-C (more than 10 ng/ml) induced apoptosis in U937 cells along with formation of apoptotic bodies and caspase-3 activation. However, treatment with the lower concentration of Ara-C (2.5 to 7.5 ng/ml) induced autophagy as assessed by electron microcopy and the punctuated distribution pattern of cytoplasmic microtubule-associated protein 1 light chain 3B (LC3B) by fluorescent immunocytochemistry. Low dose-Ara-C inducing -cell death and -autophagy both were suppressed when the cells were cultured in the presence of 3-MA. This suggests that the autophagic cell death but not the cytoprotective autophagy was induced in response to Ara-C. Combined treatment with G-CSF (lenograstim; 100 ng/ml) plus 2.5 to 7.5 ng/ml of Ara-C, but not plus higher concentrations of Ara-C, resulted in the enhanced cytocidal effect in U937 cells in vitro. These data indicate that combined treatment of Ara-C plus G-CSF has a therapeutic benefit for the AML patients by enhanced cytocidal effect which appears to be mediated via induction of autophagy. In addition, our data appear to explain in part the high response rate of CAG therapy in refractory AML, which consists of low-dose Ara-C in combination with G-CSF and aclarubicin.

Inhibition of Cytarabine in Proliferation of Human Leukemia Cloned Strains Determined by CCK-8 Assay

Aclarubicin and Low-Dose Cytosine Arabinoside in Combination with Granulocyte Colony-Stimulating Factor in Treating Acute Myeloid Leukemia Patients with Relapsed or Refractory Disease and Myelodysplastic Syndrome: a Multicenter Study of 112 Chinese Patients.

[Effects of Berbamine on K562 Cells and Its Mechanisms in Vitro and in Vivo].

Study on Taxol in Inhibiting Human Leukemia Cell Proliferation and Inducing Apoptosis

Cytarabine concentration Monitoring and its correlation to therapeutic response and prognosis in pediatric leukemia treated with high dose cytarabine

Influence of CDK4/6 on proliferation and apoptosis of acute leukemia cells

In Vitro Investigation of Effect of CAG Regimen on U937 Cell Line

Determination of Cytarabine at High-Dose and Investigation of Curative Effect in Children with Acute Leukemia

Autophagy is an Important Event for Low-Dose Cytarabine Treatment in Acute Myeloid Leukemia Cells

Comparison Of Clinical Efficacy Of Cytarabine With Different Regimens In Postremission Consolidation Therapy For Adult T(8;21) Aml Patients: A Multicenter Retrospective Study In China

Determination of Ara-C in plasma and Ara-CTP in leukemic cells after intravenous infusion of high-dose Ara-C in patients with acute leukemia and analysis of influence factors

Autophagy Induction of Acute Myeloid Leukemia (aml) Cells after Treatment with Low Dose-Cytarabine (Ara-C) and Enhanced Cytocidal Effect on Aml Cells by Combined Treatment with Ara-C Plus Lenograstim.

Curative Effect Analysis of High Dose Cytosine Arabinoside in the Chemotherapy for Childhood Acute Lymphoblastic Leukemia

In Vitro Study of the Effect of Cyclosporine A, Tetrandrine and Their Combination on the Reversion of Multidrug Resistance in Leukemia Cell Line.

Curative Effect of CAG Regimen on Patients with Untreated Acute Myeloid Leukemia and Its Mechanism

Induction of apoptosis in K562 human chronic myelogenous leukemia cells by tetra-arsenic tetra-sulfide, STI571 and herbimycin

Studies on the Effects of Berbamine on the Human Leukemia Cell Line Nb4.

Effect of fludarabine combined with cytarabine on the viability and metabolic enzymes of HL-60 cells

Effect of 8-Chloroadenosine on Undifferentiatied HL-60 Cell Line

Relationship between clinical efficacy and intracellular levels of dCK and CDA in acute leukemia

Study on mechanism of apoptosis induced by Ara-C in leukemia HL-60 cells